Bedrijfsoverzicht
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to the development and commercialization of life-transforming therapies designed for patients suffering from severe and rare diseases. The company operates within the healthcare sector, specifically focusing on the biotechnology industry, which implies a high-risk, high-reward environment centered on research and development rather than mature product revenue streams. With a market capitalization of $44.64 million, an annual revenue of $858,000, and a workforce consisting of 14 employees, the company maintains a very small operational scale relative to established pharmaceutical peers. These valuation and revenue figures indicate that Rallybio is in an early-stage growth phase where cash reserves are critical for funding clinical trials, as the current revenue level is insufficient to cover the substantial costs associated with developing lead product candidates like RLYB116.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $858,000, while recording a net income of -$8,978,000 and an EBITDA of -$31,272,000, revealing a significant gap between top-line generation and profitability. This disparity indicates a cost structure dominated by heavy research and development expenses, which is typical for clinical-stage biotechnology firms but results in substantial operating losses. Free cash flow stands at -$20,342,500, suggesting that the company is currently burning cash at a rapid rate to fund its operations and pipeline advancement, thereby limiting immediate financial flexibility. Analysis of the three primary margins shows a gross margin of 0.0%, an operating margin of -2888.3%, and a profit margin of 0.0%, all reflecting the aggressive investment phase before products reach commercial viability. The balance sheet presents a conservative leverage profile with $54.74 million in cash compared to only $176,000 in debt, supported by a debt-to-equity ratio of 0.30. Current liquidity is exceptionally strong, evidenced by a current ratio of 14.51, which indicates the company holds more than fourteen times the liquid assets required to cover its short-term obligations. Return on Equity is -15.0% and Return on Assets is -30.1%, metrics that reveal management is currently prioritizing asset accumulation and clinical progress over generating immediate returns for shareholders.
Waarderingsbeoordeling
The valuation metrics present a complex picture with a P/E Ratio (TTM) listed as N/A due to losses, while the Forward P/E is -1.56, implying that future earnings are expected to remain negative or are not yet projected to turn positive. The price-to-book ratio of 0.77 indicates that the market is valuing the company at less than its book value, a common characteristic for speculative biotechnology firms with limited tangible assets. Alternative valuation measures include a price-to-sales ratio of 52.03 and an EV/EBITDA of 0.32, suggesting that investors are pricing Rallybio based on future potential rather than current cash flows or earnings. The stock's trading range over the last year spans from a 52-week low of $1.79 to a 52-week high of $11.49, placing the current valuation context within a highly volatile band defined by these extremes. The beta value of -1.20 is anomalous for equities, indicating that the stock price moves inversely to the broader market, which introduces unique and elevated volatility risks unrelated to standard market trends.
Growth & Income
Revenue growth year-over-year stands at an impressive 484.2%, while earnings growth is N/A due to the company's consistent net losses, illustrating that top-line expansion is occurring without corresponding profitability in the current fiscal period. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available resources are reinvested into research, development, and clinical trials rather than distributed to shareholders. This reinvestment strategy is necessary for a clinical-stage entity to advance its lead product candidates and achieve the commercial milestones required for future profitability. The overall growth and income profile is defined by rapid revenue scaling fueled by market introduction or trial progress, coupled with a complete absence of current income generation or dividend distributions.